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Background: Calcific aortic stenosis is a common disorder in elderly patients with a prevalence of 2.5% at 75 years, and up to 8% at 85 years old. 
Surgical aortic valve replacement (SAVR) is the definitive proven therapy for patients with severe aortic stenosis who have symptoms or objective 
consequences left ventricular (LV) dysfunction. The development of transcatheter aortic valve implantation (TAVI) for the treatment of critical aortic 
stenosis offers a viable and “less invasive” option for patients at high risk with conventional approaches. This study was undertaken to compare the 
hemodynamic performance of TAVI to that of surgically implanted stented bio prostheses for treatment of severe aortic stenosis.
Method: Fifty patients who TAVI with the CoreValve bioprosthetic valve (CoreValve, Inc Irvine, California) were matched 1:1 for sex, aortic annulus 
diameter, left ventricular ejection fraction, body surface area and body mass index, with 58 patients who underwent SAVR. Doppler echocardiography 
data were prospectively obtained before the intervention, at discarge, and 6-to 12-month follow-up.
Results: Mean transprosthetic gradient at discarge was lower (p<0.006) in the TAVI group (11 ± 5 mmHg) compared with the SAVR (14 ± 5 mmHg) 
gruop and was confirmed at follow-up (12 ± 4 vs 15 ± 6 mmHg respectly; p<0.008). Aortic regurgitation occured more frequently in the TAVI group 
(mild 62%, moderate 2%) compared with the SAVR (mild 8%, moderate 0%) (p<0.001). At follow up the left ventricular mass index (LVMh) showed 
improvement in both groups (70 ± 20 vs 68 ± 19 g/m2.7; p>0.05). The incidence of severe prosthesis mismatch was significantly lower (p<0.004) 
in the TAVI gruop (12%) compared with the SAVR (32%). However the incidence of aortic regurgitation remained higher in the TAVI group compare 
with SAVR. LV ejection fraction improved significantly only in TAVI group at follow up (from 51.5 ± 7.8 to 55 ± 6.2 %: p<0.000)
Conclusion: TAVI provided superior hemodynamic performance compared with the surgical bioprostheses in terms of transprosthetic gradient, LV 
ejection fraction and prevention of severe prosthesis patient mismatch, but was associated with a higher incidence of aortic regurgitation.
